Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 203 Cr.
- Current Price ₹ 137
- High / Low ₹ 272 / 100
- Stock P/E 34.4
- Book Value ₹ 49.8
- Dividend Yield 0.73 %
- ROCE 13.5 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 19.4%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|
| 95.27 | 95.15 | 78.47 | 72.83 | |
| 74.56 | 73.69 | 65.10 | 63.10 | |
| Operating Profit | 20.71 | 21.46 | 13.37 | 9.73 |
| OPM % | 21.74% | 22.55% | 17.04% | 13.36% |
| 1.00 | 1.05 | 1.18 | 1.61 | |
| Interest | 0.17 | 0.82 | 0.83 | 1.19 |
| Depreciation | 1.59 | 2.04 | 2.29 | 2.76 |
| Profit before tax | 19.95 | 19.65 | 11.43 | 7.39 |
| Tax % | 25.51% | 26.92% | 26.16% | |
| 14.86 | 14.36 | 8.44 | 5.92 | |
| EPS in Rs | 10.03 | 9.70 | 5.70 | 4.00 |
| Dividend Payout % | 19.93% | 20.63% | 17.55% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | -9% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | 39.87 | 51.60 | 57.45 | 58.95 |
| 9.75 | 14.43 | 26.46 | 28.71 | |
| 19.34 | 12.38 | 11.15 | 13.98 | |
| Total Liabilities | 83.77 | 93.22 | 109.87 | 116.45 |
| 25.49 | 33.11 | 33.09 | 56.58 | |
| CWIP | 0.00 | 0.31 | 21.06 | 1.97 |
| Investments | 7.08 | 16.79 | 19.83 | 20.58 |
| 51.20 | 43.01 | 35.89 | 37.32 | |
| Total Assets | 83.77 | 93.22 | 109.87 | 116.45 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 9.16 | 14.82 | 16.54 | |
| -2.64 | -20.48 | -25.85 | |
| 3.96 | 0.96 | 7.40 | |
| Net Cash Flow | 10.49 | -4.70 | -1.91 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 72.33 | 51.56 | 71.17 |
| Inventory Days | 92.33 | 124.92 | 99.63 |
| Days Payable | 92.57 | 71.19 | 83.28 |
| Cash Conversion Cycle | 72.09 | 105.28 | 87.52 |
| Working Capital Days | 68.46 | 79.83 | 76.94 |
| ROCE % | 27.63% | 13.46% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
2d - Chemcrux confirms non-applicability of SEBI Large Corporate framework as of 31 March 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) for Q1 2025.
-
Closure of Trading Window
22 Mar - Closure of trading window from April 1, 2025.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
21 Mar - Regularisation of Mr. Rohit Kothari as Independent Director.
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
21 Mar - Regularisation of Mr. Rohit Kothari as Independent Director.
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries